China is mulling over establishing a Brain-Computer Interface (BCI) standardization technical committee under its Ministry of Industry and Information Technology (MIIT), aiming to guide enterprises to enhance industrial standards and boost domestic innovation. The proposed committee, revealed by the MIIT on Monday, will work on composing a BCI standards roadmap for the entire industry development as well as the standards for the research and development of the key technologies involved, according to the MIIT. China has taken strides in developing the BCI industry over the years, not only providing abundant policy support but also generous financial investment, Li Wenyu, secretary of the Brain-Computer Interface Industrial Alliance, told the Global Times. From last year to 2024, both the central and local governments have successively issued relevant policies to support industrial development. The MIIT in 2023 rolled out a plan selecting and promoting a group of units with strong innovation capabilities to break through landmark technological products and accelerate the application of new technologies and products. The Beijing local government also released an action plan to accelerate the industry in the capital (2024-2030) this year. In 2023, there were no fewer than 20 publicly disclosed financing events for BCI companies in China, with a total disclosed amount exceeding 150 million yuan ($20.6 million), Li said. “The strong support from the government has injected momentum into industrial innovation.” The fact that China's BCI industry started later than Western countries such as the US is a reality, leading to the gap in China regarding technological breakthroughs, industrial synergy, and talent development, according to Li. To further close gaps and solve bottlenecks in BCI industrial development, Li suggested that the industry explore various technological approaches to suit different application scenarios and encourage more medical facilities powered by BCI to initiate clinical trials by optimizing the development of BCI-related ethics. Additionally, he highlighted that standard development is one of the aspects to enhance the overall level and competitiveness of the industry chain, which could, in turn, empower domestic BCI innovation. While China's BCI technology generally lags behind leading countries like the US in terms of system integration and clinical application, this has not hindered the release of Neucyber, which stands as China's first "high-performance invasive BCI." Neucyber, an invasive implanted BCI technology, was independently developed by Chinese scientists from the Chinese Institute for Brain Research in Beijing. Li Yuan, Business Development Director of Beijing Xinzhida Neurotechnology, the company that co-developed this BCI system, told the Global Times that the breakthrough of Neucyber could not have been achieved without the efforts of the institute gathering superior resources from various teams in Beijing. A group of mature talents were gathered within the institute, from specific fields involving electrodes, chips, algorithms, software, and materials, Li Yuan said. Shrugging off the outside world's focus on China’s competition with the US in this regard, Li Yuan said her team doesn’t want to be imaginative and talk too much, but strives to produce a set of products step by step that can be useful in actual applications. In addition, Li Wenyu also attributed the emergence of Neucyber to the independent research atmosphere and the well-established talent nurturing mechanism in the Chinese Institute for Brain Research. He said that to advance China’s BCI industry, it is necessary not only to cultivate domestic talents but also to introduce foreign talents to enhance China's research and innovation capabilities. The proposed plan for establishing the BCI standardization technical committee under the MIIT will solicit public opinions until July 30, 2024.

South Korea's Minister of Health and Welfare Cho Kyu-hong said at a press conference on the 8th local time that after comprehensively considering the suggestions of frontline interns and the situation on the front line of medical care, the government decided that from that day on, all interns and residents who resigned would not be given administrative sanctions such as revoking their medical licenses. Cho Kyu-hong also said that for interns and residents who have returned to work and those who have resigned and are preparing to re-register for internship courses in September, the government will make special cases to try to minimize the internship gap and not affect the relevant doctors from obtaining specialist medical licenses. Cho Kyu-hong said that the government believes that in order to minimize the diagnosis and treatment gaps for critically ill and emergency patients and ensure the smooth training process of interns and residents, it is in the public interest, so it has made a decision not to punish interns and residents who resigned. It is hoped that major hospitals will complete the resignation processing of doctors who have not returned to work before July 15 and determine the scale of vacancies. Previously, large general hospitals in South Korea, such as Seoul National University Hospital, Yonsei University Severance Hospital, and Seoul Asan Medical Center, suspended or limited their medical services in an effort to cancel all penalties against interns and residents.

WASHINGTON, July 8 (Reuters) - The planet known as HD 189733b, discovered in 2005, already had a reputation as a rather extreme place, a scorching hot gas giant a bit larger than Jupiter that is a striking cobalt blue color and has molten glass rain that blows sideways in its fierce atmospheric winds. So how can you top that? Add hydrogen sulfide, the chemical compound behind the stench of rotten eggs. Researchers said on Monday new data from the James Webb Space Telescope is giving a fuller picture of HD 189733b, already among the most thoroughly studied exoplanets, as planets beyond our solar system are called. A trace amount of hydrogen sulfide was detected in its atmosphere, a first for any exoplanet. "Yes, the stinky smell would certainly add to its already infamous reputation. This is not a planet we humans want to visit, but a valuable target for furthering our understanding of planetary science," said astrophysicist Guangwei Fu of Johns Hopkins University in Baltimore, lead author of the study published in the journal Nature, opens new tab. It is a type called a "hot Jupiter" - gas giants similar to the largest planet in our solar system, only much hotter owing to their close proximity to their host stars. This planet orbits 170 times closer to its host star than Jupiter does to the sun. It completes one orbit every two days as opposed to the 12 years Jupiter takes for one orbit of the sun. In fact, its orbit is 13 times nearer to its host star than our innermost planet Mercury is to the sun, leaving the temperature on the side of the planet facing the star at about 1,700 degrees Fahrenheit (930 degrees Celsius). "They are quite rare," Fu said of hot Jupiters. "About less than one in 100 star systems have them." This planet is located 64 light-years from Earth, considered in our neighborhood within the Milky Way galaxy, in the constellation Vulpecula. A light-year is the distance light travels in a year, 5.9 trillion miles (9.5 trillion km). "The close distance makes it bright and easy for detailed studies. For example, the hydrogen sulfide detection reported here would be much more challenging to make on other faraway planets," Fu said. The star it orbits is smaller and cooler than the sun, and only about a third as luminous. That star is part of a binary system, meaning it is gravitationally bound to another star. Webb, which became operational in 2022, observes a wider wavelength range than earlier space telescopes, allowing for more thorough examinations of exoplanet atmospheres.

LONDON, July 9 (Reuters) - U.S.-based hedge fund Elliott Associates on Tuesday urged a London court to overturn a verdict supporting the London Metal Exchange's (LME) cancellation of nickel trades partly because the exchange failed to disclose documents. The LME annulled $12 billion in nickel trades in March 2022 when prices shot to records above $100,000 a metric ton in a few hours of chaotic trade. Elliott and market maker Jane Street Global Trading brought a case demanding a combined $472 million in compensation, alleging at a trial in June last year that the 146-year-old exchange had acted unlawfully. London's High Court ruled last November that the LME had the right to cancel the trades because of exceptional circumstances, and was not obligated to consult market players prior to its decision. Lawyers for Elliott told London's Court of Appeal that the LME belatedly released documents in May detailing its "Kill Switch" and "Trade Halt" internal procedures. It also newly disclosed an internal report that Elliott said detailed potential conflicts of interest at the exchange. "It was troubling that one gets disclosure out of the blue in the Court of Appeal for the first time," Elliott lawyer Monica Carss-Frisk told the court. Jane Street Global did not appeal the ruling. "If we had had them (documents) in the proceedings before the divisional court, we may well have sought permission to cross examine." LME lawyers said the new documents were not relevant. "The disclosed documents do not affect the reasoning of the divisional court or the merits of the arguments on appeal," the exchange said in documents prepared for the appeal hearing. "Elliott's appeal is largely a repetition of the arguments which were advanced, and rightly rejected." The LME said it had both the power and a duty to unwind the trades because a record $20 billion in margin calls could have led to at least seven clearing members defaulting, systemic risk and a potential "death spiral". Elliott said the ruling diluted protection provided by the Human Rights Act and also wrongly concluded the LME had the power to cancel the trades.

The world's first portable electrocardiograph was an 85-pound backpack, and now a 10-gram patch attached to your chest can transmit electrocardiograms uninterrupted for two weeks. The Apple Watch, which is worn by an estimated 100 million people, can send a text message to alert people when their heartbeat is irregular. Wearable sensors on the arms, wrists and fingers can now report arrhythmias, blood sugar levels, blood oxygen and other health indicators. Medical journals have also proposed a more ambitious vision - wearable devices can monitor patients with chronic diseases, eliminating the need for frequent hospital visits. They can spot potential health problems before a stroke or diabetes develops. The forces of health technology and wearables are converging. Tech giants like Apple (AAPL) and Alphabet's (GOOGL) Google are adding health features to their products. Medical technologists like electrocardiogram patch maker iRhythm Technologies or blood sugar monitor makers DexCom (DXCM) and Abbott Laboratories (ABT) are taking their devices beyond the clinic. "In the sensor world, people started on the consumer side and wanted to get into health care," said Kevin Sayer, chief executive of Decon Medical. "In health care, we're trying to be more consumer oriented, and I think all of those things are sort of colliding." Early bets favored the tech giants, with every health-related announcement from Apple, Google or Samsung Electronics hitting medical tech stocks. But changing doctors' practices will also require sustained investment in clinical trials. Big tech companies have cut back on investments in health care. Now it seems that medical technologists will be at the vanguard of the digital health revolution - with smartwatches and smart rings bringing them more customers who need to be diagnosed. Blake Goodner, co-founder of Bridger Management, a hedge fund focused on health care, said: "A group of medtech companies focused on digital health are maturing and reaching a scale where they can not only be profitable but also make investments to compete with larger tech companies." Tech giants aren't getting out of the health business. Apple's smartwatch has an electronic heart rate sensor that generates a single-point electrocardiogram, a wrist temperature sensor, and an accelerometer that can detect violent falls. Hundreds of millions of people are wearing smartwatches with health features from Apple or its rivals Samsung and Garmin.